Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 20 versus SOJOURN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 20 versus SOJOURN.
LARIN 1/20 vs SOJOURN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.
400 mg orally once daily
None Documented
None Documented
Norethindrone: 7.6 hours (range 5-14); Ethinyl estradiol: 13.2 hours (range 8-20). Clinical context: Steady-state achieved within 5-10 days.
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
Approximately 60% renal (30% norethindrone, 30% ethinyl estradiol metabolites) and 40% fecal (biliary excretion of conjugates).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive